Cigna (CI) Q2 Revenue Jumps 11%

Cigna Group (NYSE:CI) reported strong second-quarter 2025 results, with non-GAAP revenue of $67.2 billion and adjusted EPS of $7.20, both significantly exceeding analyst estimates, primarily driven by 17% adjusted revenue growth in Evernorth Health Services. While the company demonstrated robust top-line performance and improved cost efficiency, overall profit margins moderated, and the Cigna Healthcare segment's revenue declined 18% due to a Medicare business divestiture. Despite beating expectations, management reaffirmed its full-year guidance, signaling ongoing pressures from rising medical costs and narrowing Evernorth margins, making these areas key for investor monitoring alongside strategic portfolio adjustments.

Analysis

The Cigna Group (CI) reported a robust second quarter for 2025, with non-GAAP revenue of $67.2 billion and adjusted EPS of $7.20, beating analyst consensus by 7.3% and $0.04 respectively. The primary growth driver was the Evernorth Health Services segment, which delivered a 17% year-over-year increase in adjusted revenue to $57.8 billion, fueled by strong client expansion in pharmacy benefit services. However, this top-line strength was offset by a notable contraction in Evernorth's pre-tax adjusted margin, which narrowed to 2.9% from 3.3% a year prior. In the Cigna Healthcare segment, the 18% decline in adjusted revenue was an expected consequence of the divested Medicare business; on a comparable basis, revenue grew a solid 7%. A key headwind in this segment was the rise in the medical care ratio (MCR) to 83.2% from 82.3%, attributed to higher stop-loss medical costs. Despite these pressures, the company demonstrated strong operational efficiency, reducing its adjusted SG&A expense ratio to 4.9% from 6.0%. Critically, management reaffirmed its full-year EPS guidance of at least $29.60, choosing not to raise it despite the quarterly beat, signaling caution regarding ongoing cost pressures and margin challenges.

Key Decisions for Investors

• Investors should closely monitor margin trends in the Evernorth segment, as its profitability is contracting despite being the primary engine for revenue growth.
• The decision to reaffirm rather than raise full-year guidance, despite the Q2 beat, signals management's caution on rising medical costs and suggests upside may be limited until these pressures subside.
• Monitor Cigna Healthcare's medical care ratio (MCR) in subsequent quarters, as its increase to 83.2% is a direct indicator of profitability pressure within the core insurance business.
• Given the strong capital return program, including $2.6 billion in share repurchases, investors should weigh this shareholder-friendly activity against the fundamental operating headwinds and external regulatory risks facing the PBM industry.